M-M-RvaxPro (measles, mumps and rubella vaccine (live)) / Merck (MSD) - LARVOL DELTA

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1092 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Implementing an MMR vaccination programme for adults living with HIV in response to a measles outbreak in London, UK (IAS-HIV 2025) - "We offered both the MMRVAXPRO and PRIORIX vaccines to provide an alternative for clients who declined porcine gelatine. Integrating measles immunity testing and MMR vaccination into routine HIV care is feasible. It ensures ease of access to vaccination and promotes vaccine uptake, improving health outcomes for people living with HIV."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Measles • CD4

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1080 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1080 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Measles-mumps-rubella-vaccination at 6 months of age induces measles-specific T cell responses: a randomized controlled trial. (PubMed, Front Immunol) - P4 | "Participants were randomized 1:1 to receive M-M-RVaxPro or placebo...Early MMR could help reduce measles burden in infants in endemic settings without compromising subsequent immunizations. ClinicalTrials.gov, identifier NCT03780179, EudraCT 2016-001901-18."

Clinical • Journal • Infectious Disease • Measles • Mumps • Rubella • IFNG

Measles-mumps-rubella vaccination at 6 months of age and the risk of atopic disease in the first year of life: Results from a Danish placebo-controlled randomised trial. (PubMed, J Infect) - P4 | "Based on trial data in 6,540 Danish infants randomised to MMR or placebo at 5-7 months, no association between MMR and atopic disease in early childhood was observed."

Journal • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatology • Immunology • Infectious Disease • Measles • Mumps • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Rubella

Immunogenicity and reactogenicity following MMR vaccination in 5-7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants. (PubMed, EClinicalMedicine) - P4 | "Healthy 5-7-month-old Danish infants were assigned in a 1:1 ratio to M-M-RVaxPro or placebo (solvent) in a double-blind, randomized trial between April 15, 2019 and November 1, 2021 (ClinicalTrials.govNCT03780179, EudraCT 2016-001901-18)...MMR at 5-7 months was safe and not associated with higher rates of reactogenicity than placebo. Innovation Fund Denmark."

Clinical • Journal • Infectious Disease • Measles • Mumps • Rubella

MIPS: Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: University of Zurich | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2023 ➔ Dec 2023

Enrollment open • Trial initiation date • Infectious Disease • Measles • Mumps • Rubella

MIPS: Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination (clinicaltrials.gov) - P3 | N=200 | Not yet recruiting | Sponsor: University of Zurich

New P3 trial • Infectious Disease • Measles • Mumps • Rubella • IFNG

Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial. (PubMed, BMJ) - P4 | "Findings of this trial conducted in Denmark, a high income setting, do not support the hypothesis that live attenuated MMR vaccine administered early to infants aged 5-7 months decreases the rate of hospitalisations for non-targeted infection before age 12 months."

Journal • Infectious Disease • Influenza • Measles • Mumps • Pertussis • Respiratory Diseases • Rubella • Tetanus